Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Adynamic Bone Disorder with Teriparatide in CKD
2023-506853-39-00Phase 4Authorised
- Sponsor
- Herlev Hospital
- Start
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of teriparatide in adynamic bone disease (ABD) (2 arms), sponsored by Herlev Hospital. Planned start Jul 2023; status: authorised.
02
Drugs
teriparatide
03
Conditions
adynamic bone disease (ABD)
Beyond the preview
Go deeper on 2023-506853-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506853-39-00.